Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Pembrolizumab, Olaparib and Temozolomide for the Treatment of Recurrent Glioblastoma

Trial Status: active

This phase II trial tests how well the combination of pembrolizumab, olaparib and temozolomide works in treating patients with glioblastoma that that has come back (recurrent). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Olaparib is a PARP inhibitor. PARP is a protein that helps repair damaged DNA. Blocking PARP may prevent cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Temozolomide is a chemotherapy drug that can enter the brain and prevent tumor cells from growing by causing DNA damage. The combination of pembrolizumab, olaparib and temozolomide may be an effective treatment for patients with recurrent glioblastoma.